Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
D006585:Altretamine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004341:Drug Evaluation; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D011897:Random Allocation; D012552:Schistosomiasis / Q000150:complications; D013997:Time Factors; D014227:Triazines / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000188:drug therapy*
D000970:Antineoplastic Agents; D014227:Triazines; D006585:Altretamine; C022048:pentamethylmelamine